Loretta Nastoupil, MD

Financial relationships

  • Attribution:
    Self
    Nature of financial relationship:
    Professional Services
    Ineligible company:
    Abbvie
    Topic:
    Drug Development B cell lymphoma
    Date added:
    01/22/2025
    Date updated:
    01/22/2025
    Relationship end date:
    07/01/2024
  • Attribution:
    Self
    Nature of financial relationship:
    Professional Services
    Ineligible company:
    Astra Zeneca
    Topic:
    Drug Development B cell lymphoma
    Date added:
    01/22/2025
    Date updated:
    01/22/2025
    Relationship end date:
    07/01/2024
  • Attribution:
    Self
    Nature of financial relationship:
    Professional Services
    Ineligible company:
    BMS
    Topic:
    Drug Development B cell lymphoma
    Date added:
    01/22/2025
    Date updated:
    01/22/2025
    Relationship end date:
    07/01/2024
  • Attribution:
    Self
    Nature of financial relationship:
    Professional Services
    Ineligible company:
    Caribou Biosciences
    Topic:
    Drug Development B cell lymphoma
    Date added:
    01/22/2025
    Date updated:
    01/22/2025
    Relationship end date:
    07/01/2024
  • Attribution:
    Self
    Nature of financial relationship:
    Professional Services
    Ineligible company:
    Daiichi Sankyo
    Topic:
    Drug Development B cell lymphoma
    Date added:
    01/22/2025
    Date updated:
    01/22/2025
    Relationship end date:
    07/01/2024
  • Attribution:
    Self
    Nature of financial relationship:
    Professional Services
    Ineligible company:
    Genentech
    Topic:
    Drug Development B cell lymphoma
    Date added:
    01/22/2025
    Date updated:
    01/22/2025
    Relationship end date:
    07/01/2024
  • Attribution:
    Self
    Nature of financial relationship:
    Professional Services
    Ineligible company:
    Gilead/Kite
    Topic:
    Drug Development B cell lymphoma
    Date added:
    01/22/2025
    Date updated:
    01/22/2025
    Relationship end date:
    07/01/2024
  • Attribution:
    Self
    Nature of financial relationship:
    Professional Services
    Ineligible company:
    Ipsen
    Topic:
    Real world Analyses
    Date added:
    01/22/2025
    Date updated:
    01/22/2025
    Relationship end date:
    02/15/2024
  • Attribution:
    Self
    Nature of financial relationship:
    Professional Services
    Ineligible company:
    Janssen
    Topic:
    Drug Development B cell lymphoma
    Date added:
    01/22/2025
    Date updated:
    01/22/2025
    Relationship end date:
    07/01/2024
  • Attribution:
    Self
    Nature of financial relationship:
    Professional Services
    Ineligible company:
    Merck
    Topic:
    Drug Development B cell lymphoma
    Date added:
    01/22/2025
    Date updated:
    01/22/2025
    Relationship end date:
    07/01/2024

Pages

Return to 14th Annual Updates in the Treatment and Management of Hematologic Malignancies Highlights from San Diego